4.8 Article

The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes

Journal

NATURE COMMUNICATIONS
Volume 7, Issue -, Pages -

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/ncomms11479

Keywords

-

Funding

  1. Cancer Research UK
  2. British Columbia Cancer Foundation
  3. Canadian Breast Cancer Foundation BC/Yukon
  4. CRUK [C507/A16278]
  5. Illumina UK
  6. University of Cambridge, Hutchinson Whampoa
  7. NIHR Cambridge Biomedical Research Centre
  8. Cambridge Experimental Cancer Medicine Centre
  9. Centre for Translational Genomics (CTAG) Vancouver
  10. BCCA Breast Cancer Outcomes Unit
  11. National Institute for Health Research Cambridge Biomedical Research Centre
  12. Cancer Research UK [S_2464, 9675, 20240, 16942] Funding Source: researchfish
  13. Cancer Research UK
  14. The Francis Crick Institute [10124] Funding Source: researchfish
  15. National Breast Cancer Foundation [ECF-14-027] Funding Source: researchfish
  16. National Institute for Health Research [NF-SI-0611-10154, ACF-2009-12-003, CL-2010-12-003, NF-SI-0515-10090, ACF-2012-14-006] Funding Source: researchfish
  17. The Francis Crick Institute
  18. Cancer Research UK [10119] Funding Source: researchfish

Ask authors/readers for more resources

The genomic landscape of breast cancer is complex, and inter-and intra-tumour heterogeneity are important challenges in treating the disease. In this study, we sequence 173 genes in 2,433 primary breast tumours that have copy number aberration (CNA), gene expression and long-term clinical follow-up data. We identify 40 mutation-driver (Mut-driver) genes, and determine associations between mutations, driver CNA profiles, clinical-pathological parameters and survival. We assess the clonal states of Mut-driver mutations, and estimate levels of intra-tumour heterogeneity using mutant-allele fractions. Associations between PIK3CA mutations and reduced survival are identified in three subgroups of ER-positive cancer (defined by amplification of 17q23, 11q13-14 or 8q24). High levels of intra-tumour heterogeneity are in general associated with a worse outcome, but highly aggressive tumours with 11q13-14 amplification have low levels of intra-tumour heterogeneity. These results emphasize the importance of genome-based stratification of breast cancer, and have important implications for designing therapeutic strategies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available